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History of IgD 
Dr. David Rowe, MD and Dr. John Fahey, MD were studying the disease multiple 
myeloma in humans in 1964 when they made a fantastic discovery. During analysis 
they were able to identify and characterize an atypical myeloma protein that displayed 
no cross reactivity to the anti-serum of the currently known human immunoglobulin 
classes (IgM, IgG, IgA). This atypical myeloma protein had unique metabolic and 
electrophoretic qualities in comparison to the other known Ig classes (1). Following up 
on their initial discovery, an antigenically related protein in the serum of healthy 
individuals was identified in lower concentration than the myeloma patients that did not 
share the antigenic characteristics of the other Ig classes. This suggested to Rowe and 
Fahey that the newly discovered protein was not a subclass of the currently known Ig 
classes or abnormal product of the myeloma cells but was in fact a novel Ig class that 
displayed distinct properties in the heavy polypeptide chains. Because these uniquely 
distinctive properties were enough evidence to differentiate the novel protein from the 
currently known Ig classes both Rowe and Fahey thought it was appropriate that the 
protein should be named IgD (2). While Rowe and Fahey did have limited options for 
picking the name of the new Ig class, the name IgD was a good choice for this antibody 
because in addition to being distinctive from the other Ig classes, this protein also 
displays a large amount of diversity in glycosylation between groups of individuals as 
well as within single individuals. 
 Following its initial discovery, further studies were conducted during the late 
1970’s and early 1980’s to identify the other species that also contained IgD. Initially the 




rabbits but were not able to locate any IgD in birds or pigs (3-6). However, due to the 
technological advances that have accompanied the course of time, scientists have been 
able to identify a wide variety of additional species with IgD including: pigs, sheep, 
cattle, amphibians, reptiles, birds, bony fish, cartilaginous fish. The oldest of the species 
that express IgD are the cartilaginous fish which first appeared on earth about 470 
million years ago. The continued preservation of IgD throughout evolution solidifies that 
its presence plays a role in critical biological functions and provides survival advantages 
to the host (7-24).  
 
Induction and Expression of IgD 
 Immunoglobulin D (IgD) is an enigmatic protein that is solely produced by the B 
cells of the adaptive immune system. IgD is not produced throughout the entirety of B 
cell development and our B cells utilize multiple strategies to induce its expression. 
During the early stages of B cell development, the only immunoglobulin that is 
expressed is IgM. B cells first begin to express IgD when the immature B cells begin to 
exit the bone marrow in search of the secondary lymphoid organs. Upon egression from 
the bone marrow into the periphery, B cells utilize alternative RNA splicing to co-
express both IgM and IgD on the cell surface with IgD being expressed at a higher level 
than IgM (25). This co-expression of IgM and IgD is maintained in both transitional and 
mature B cells until the cells experience antigenic stimulation. Following antigenic 
stimulation, most mature B cells will begin to quickly downregulate their surface IgD 
expression and undergo a process known as class switch recombination (CSR) in order 
to solely express either IgG, IgA or IgE depending on the antigenic signals they 




IgE, some of the mature B cells will in fact undergo CSR to only express IgD. These 
class switched B cells will eventually differentiate into cells known as plasmablasts. 
During differentiation into plasmablasts, the class switched B cells will down regulate 
their respective membrane bound immunoglobulins from the cell surface. After 
differentiation into plasmablasts is completed, the cells will begin to secrete large 
quantities of their respective immunoglobulins into circulation, where the antibodies will 
carry out various effector functions (26).  
 The co-expression of IgM and IgD by alternative RNA splicing is a strictly 
monitored event by the B cell. Initially, a long primary mRNA transcript will be generated 
that contains the rearranged VDJ exons, the Cμ exons and the Cδ exons. If the long 
primary mRNA transcript is spliced to the first Cμ exon, it will eventually result in the 
production of IgM. If the long primary mRNA transcript is spliced to the first Cδ exon, it 
will eventually result in the production of IgD (27). The amount of μ and δ exon 
transcription does not always correlate to the cell surface expression levels of IgM and 
IgD. It has been observed in some types of B cells that even though there are more μ 
mRNA transcripts than there are δ mRNA transcripts, there is still higher protein 
expression of IgD at the cell surface than the IgM protein. This is thought to be the 
result of a higher turnover rate of membrane bound IgM compared to the membrane 
bound IgD turnover rate. Additionally, it is thought that there is an increase in the δ 
mRNA stability and an increase in the efficiency of δ mRNA translation when compared 
to μ mRNA (25, 28, 29). Conversely, in B cells that are experiencing antigenic 
stimulation, μ exon transcription and alternative RNA splicing to the Cμ exon are 
specifically upregulated while δ exon transcription and IgD expression is significantly 




in the germinal centers of secondary lymphoid tissues. Additionally there are 
publications that have identified a unique region between the μ and δ genes which has 
the ability to impair the transcription complex before reaching the δ exons, thus 
specifically promoting the production of μ mRNA, completely halting the production of δ 
mRNA and ultimately leading to an exclusive increase in membrane bound IgM 
expression (30, 31).  
The expression of IgD by CSR is unique in comparison to the other antibody 
isotypes. There is not a typical switch region located 5’ to the Cδ exons like there is for 
the other antibody classes which originally led to the belief that IgD CSR was a rare 
event, however a study utilizing normal human tonsil B cells was able to identify a G-
rich pentameric repeat region between the Cμ exons and the Cδ exons that can act as 
an atypical switch region to facilitate IgD CSR and Cμ exon deletion (32). These results 
provided the information necessary to contradict the previous belief that IgD CSR was a 
rare event, however the overall regulation of IgD CSR was still poorly understood until 
Chen et al. was able to shed a huge amount of light on the mystery (33).  
They were able to identify both T-cell dependent and T-cell independent 
pathways for B cell IgM to IgD CSR in the human upper respiratory mucosa by showing 
that B cells required CD40L, B-cell activating factor (BAFF), or a proliferation-inducing 
ligand (APRIL) signals, along with the cytokine signal combination of IL-15 and IL-21 or 
IL-2 and IL-21 to undergo IgM to IgD CSR. Furthermore, they demonstrated that the B-
cell protein activation-induced cytidine deaminase (AID) was required for IgM to IgD 
CSR to occur and that AID activity resulted in the production of both mucosal and 
circulating IgD plasmablasts that secrete IgD (33). These were ground breaking results 




Structural Characteristics of IgD 
IgD has several unique characteristics that differ from the typical antibody 
structure of other Ig isotypes. Human IgD consists of 2 light chains and 2 heavy chains 
with there being 3 constant (Cδ) domains in the heavy chains, while mouse IgD contains 
one less Cδ domain than humans. The human Cδ1 and the Cδ2 domains are very similar 
to the C domains of other Ig classes, however Cδ3 is distinctive from the others because 
it contains two noteworthy N-linked glycosylation sites: Asn445 and Asn496 (34). The 
Cδ3 domain also does not contain several prolines that are typically crucial for turns in 
the polypeptide backbone. It has been proposed by multiple groups that these features 
contribute to the unique biological properties of IgD (34-36). Another unique 
characteristic of IgD is its hinge region. The human IgD hinge region is the longest 
hinge region of all the human antibody classes. When characterizing the IgD hinge 
region it can be divided into 2 sections. The first section is a threonine- and alanine-rich 
section that has a large amount of O-linked glycosylations that contain N-
acetylgalactosamine groups within the O-linked glycans. Both the O-linked 
glycosylations of the hinge region and the N-linked glycosylations of the Cδ3 domain 
can account for up to 15% of the total molecular weight of IgD. The second section of 
the hinge region contains a plethora of charged amino acids including serine (Ser), 
threonine (Thr), glutamatic acid (Glu), and lysine (Lys). This densely charged section of 
the antibody hinge region is only found in IgD and is largely responsible for the 
hydrophilic nature of the protein (37-41). Additional IgD hinge region features were 
elucidated after performing constrained X-ray scattering on the protein. The constrained 
X-ray scattering revealed that, while the other antibody isotypes adopt a Y-shaped 




shaped structure. This T-shaped structure allows the Fab fragments of IgD to be 
extremely mobile/flexible, and the associated motion of this Fab flexibility can 
shield/hide the Fc fragment (42). These structural characteristics provide valuable 
insight to the functional capabilities of IgD.  
 
Functions of IgD 
 For the most part, the functions of IgD largely remain a mystery but some of the 
functions carried out by IgD have been defined by previous studies. Originally IgD was 
thought to only function as a transmembrane B-cell antigen receptor. Utilizing 
transgenic mice, it was demonstrated by Lutz et al. that IgD could largely substitute for 
the loss of IgM function in B cells and vice versa (43). Although IgD-deficient mice had 
no observable defect in B-cell function, aside from a slightly delayed antibody response 
in comparison to wild type mice, they did however have a 30-50% reduction in 
peripheral mature B cells, indicating that IgD had a large impact on B cell homeostasis 
(44, 45). Furthermore, while transmembrane IgD and IgM have the same 3 cytoplasmic 
amino acids they are affiliated with different signaling molecules which may lead to 
different functions based on different signaling combinations between IgD and IgM (40). 
Additionally, it has been shown that IgD can be post-translationally linked to 
transmembrane lipids by a glycosylphosphatidylinositol (GPI) anchor, which ultimately 
initiate different signaling pathways than transmembrane IgD without the GPI anchor. 
The GPI-anchored IgD specifically activates cAMP signaling pathways and works 
together with transmembrane IgM and IgD to commence Ca2+-dependent signaling (46, 
47). The functional advantage to having both IgD and IgM with the same antigen 




has proposed a model that may provide some explanation. Their model suggests that 
IgD and IgM are preferentially utilized for capturing antigen at different antigen 
concentrations and this assertion is supported by the solved protein structure of the T- 
shaped IgD, showing that IgD is better suited to bind antigen at lower concentrations 
because the Fab fragments have a large amount of flexibility due to the uniquely long 
IgD hinge region (42, 48).  
Over the years, the functions of membrane bound IgD have gained most of the 
research attention, while the functions of secreted IgD have been largely overlooked. 
Soon after IgD’s discovery the literature suggested that there were some fascinating 
associations between secreted IgD and the myeloid cell lineage (49-53). Furthermore, 
an increase in serum concentration of secreted IgD was typically observed in patients 
suffering from autoimmune diseases such as rheumatoid arthritis (RA) and systemic 
lupus erythematosus (SLE) (54). Several years later it was shown that not only was 
their autoreactive IgD in autoimmune diseases, but that autoreactive IgD secreted by 
IgD class switched B-cells was regularly detectable in healthy individuals (55). This 
information laid the necessary frame work for Chen and colleagues to discover a major 
function of secreted IgD. The monumental discovery they made was that circulating 
secreted IgD enhanced immune system surveillance by binding to a calcium-mobilizing 
receptor on the surface of basophils. The binding of IgD to basophils enhanced immune 
system surveillance by inducing basophils to secrete antimicrobial, opsonizing, 
proinflammatory and B-cell stimulating factors such as: cathelicidin, interleukin 1(IL-1), 
IL-4, and BAFF. Not only did they show that secreted IgD was capable of actively 
binding to and communicating with basophils, but they also showed that IgD was 




catarrhalis and Haemophilus influenzae (33). These data combined suggest that 
secreted IgD may be able to educate basophils on the pathogenic and commensal 
composition of the respiratory tract. Following the initial monumental discovery that 
secreted IgD enhanced immune system surveillance by binding to a receptor on the 
surface of basophils, it was later determined by mass spectrometry that the basophil 
surface receptor responsible for binding IgD was in fact galectin-9 (56).  
Moreover, upon careful examination of the previously published literature it 
appears that an additional function of secreted IgD was speculated back in 1985. 
Salonen and colleagues were studying the kinetics of specific IgA, IgD, IgE, IgG and 
IgM antibody responses to rubella infection when they came across some interesting 
data. Upon analyzing the serum from a mother who had previously suffered a rubella 
infection they were able to detect rubella specific IgG and rubella specific IgD in both 
maternal and umbilical cord blood serum samples (57). This observation suggested that 
IgD may be capable of crossing the placenta, but Salonen and colleagues did not 
provide any other data to support this claim and they were never able to definitively 
prove this speculation. 
 
Maternal Vaccination 
Infectious disease continues to be a leading cause of death for children aged 0 to 
5years old. The World Health Organization reported in 2014 that almost 30 percent of 
all deaths worldwide by children under the age of 5 were caused by vaccine preventable 
disease (58). Vaccination prior to infection is a highly effective way of preventing these 
tragically unnecessary deaths, however newborn infants do not efficiently mount a 




immunization leaves newborns extremely vulnerable until their immune system is 
developed enough to begin receiving vaccinations (59). As of 2011, the Center for 
Disease Control began recommending the strategy of maternal vaccination to confront 
the vulnerability of the neonatal immune system (60). The ideology of maternal 
vaccination is that by immunizing the mother during gestation, she will effectively mount 
a vaccine-induced humoral immune response generating vaccine-specific IgG. This 
vaccine-specific IgG will then be transferred to the fetus in utero, as well as after birth 
during breastfeeding, thus providing the necessary immune protection to the vulnerable 
newborn child.  Currently the Advisory Committee on Immunization Practices (ACIP) at 
the CDC highly recommends two immunizations for all pregnant women including the 
inactivated influenza vaccine (IIV) as well as the Tetanus-diptheria-pertussis (Tdap) 
vaccine. The maternal immunization of Tdap is universally recommended to all pregnant 
women because children younger than 6 months old are at the utmost risk for 
hospitalization and death by Bordetella pertussis (61). In the United States it is 
recommended that mothers be vaccinated for pertussis between 27 and 36 weeks of 
gestation and there are no reported negative outcomes to the neonate regardless of 
maternal vaccination schedule (62). 
 
B-cell Changes During Pregnancy 
 Pregnancy has a profound effect on humoral immunity both systemically and 
locally within the reproductive tract. Many of these alterations to the humoral immune 
system have been shown to be facilitated by pregnancy steroid hormones, more 
specifically estrogen and human chorionic gonadotropin (hCG). Initially it was 




bone marrow are significantly reduced, presumably due to the increase in estrogen 
associated with pregnancy (63-67). However, the mature B cells of these pregnant mice 
had normal or even slightly elevated amounts of mature B cells, suggesting that these 
mature B cells are exempt from estrogen sensitivity (63, 64). Later, it was shown by 
multiple research groups that not only did estrogen result in a significant reduction of B 
cell precursors but that estrogen had the opposite effect on the mature B cell 
population, with one group showing that estrogen causes a significant increase in the 
development of mature B cells into plasmablasts, and another group demonstrating that 
estrogen caused a significant expansion of both marginal zone and follicular B cells (68-
70). However, estrogen is not the only pregnancy hormone that has been shown to 
have modulatory effects on humoral immunity. Recently, Fettke and colleagues showed 
that hCG, but not estrogen or progesterone, could induce the development of IL-10 
producing B cells (Breg) and it has been indicated that these Breg cells play a crucial role 
in pregnancy protection from preterm birth (PTB) (71, 72). However, there are other 
mechanisms utilized by B cells, independent of IL-10 production, that protect against 
PTB. For instance, the CD5+ B-cell population is significantly reduced during normal 
healthy pregnancy and a lack of reduction in CD5+ B-cells is associated with not only 
PTB but also with pre-eclampsia and recurring spontaneous abortions (RSA) (72-76). 
The CD5+ B-cell population contains enhanced autoreactivity and the mechanism for 
cell reduction during pregnancy is still unknown. Furthermore, Huang and colleagues 
recently discovered a novel protective role of B-cells during pregnancy. They showed 
that decidual B-cells produced a large amount of progesterone induced blocking factor 1 
(PIBF1) which was extremely critical for the prevention of PTB and this PTB prevention 





Placental Transfer of Maternal Immunity  
 The cornerstone of maternal vaccination is that vaccine-induced maternal IgG 
will be transferred across the placenta providing passive immune protection to the fetus 
prior to birth. It is transferred across the placenta through a receptor-mediated 
transcytosis mechanism. The receptor utilized by IgG to effectively cross the placenta is 
the neonatal Fc receptor (FcRn) that is expressed by trophoblasts at the maternofetal 
interface. The pathway for placental transfer of maternal IgG has been widely studied 
and well defined (78-80). The pathway begins with the syncytiotrophoblasts internalizing 
maternal IgG into early endosomes. The maternal IgG remains unbound to FcRn until 
they both become completely encapsulated by the early endosome. Once completely 
encapsulated, the pH of the early endosome significantly drops and it is the acidic pH 
that is responsible for allowing IgG to bind to FcRn. If there is any unbound IgG located 
within the acidic pH of the early endosome it will eventually be targeted to a lysosome 
for degradation. The bound IgG-FcRn complex within the early endosome can then be 
either recycled back to the maternal blood or can undergo transcytosis to the fetal side 
of the syncytiotrophoblast. This transcytosed IgG is then released by FcRn under 
neutral pH where it then enters the fetal villous stroma and ultimately makes its way into 
fetal circulation through a mechanism that is still unclear. The FcRn located on the fetal 
side of the syncytiotrophoblast can also be retrieved and recycled back to the maternal 
side of the synctiotrophoblast for additional IgG transcytosis (81). There is a direct 
correlation between the maternal concentration of IgG and the amount of IgG that is 
transferred to the fetus. Furthermore, there are preferences for the transcytosis of IgG 




and IgG3 (82).Consequently, it is no surprise that inactivated protein antigen vaccines 
such as Tdap, which generally elicit a more pronounced induction of IgG1 and IgG3, are 
considered more effective for maternal vaccination that polysaccharide vaccines which 
mainly induce an IgG2 response (83).  The largest amount of IgG transfer from mother 
to fetus has been shown to occur in the third trimester of pregnancy, however maternal 
IgG can be transferred to the fetus as early as gestational week 13 (84, 85). 
   
Goal of This Study  
 The goal of this work is to change the widespread ideology of antibody transfer 
across the placenta. Currently it is universally believed that IgG is the only antibody 
capable of crossing the placenta, but this work includes experimental data that suggests 

















Immunoglobulin D undergoes placental transfer to the fetus 
 
ABSTRACT 
 Immunoglobulin D is a mysterious protein that has largely been overlooked since 
its discovery. It is uniquely distinct from all the other antibody classes in: expression, 
induction, structure and function. Within the last few years IgD has made its way back 
into the spotlight and novel functions of the protein have been discovered. These recent 
discoveries have provided the necessary information for us to uncover an additional and 
important function of IgD during pregnancy. It is a long-held belief among scientists that 
during pregnancy the only antibody class that can cross the placenta is IgG, however 
our data shows that this common place ideology is not correct. We find that IgD is fully 
capable of crossing the placenta and that vaccine-specific IgD induced by maternal 
vaccination undergoes placental transfer to the fetus.   
 
INTRODUCTION 
  Immunoglobulin D (IgD) is an enigmatic protein that is solely produced by the B 
cells of the adaptive immune system. While IgM is the only antibody expressed on the 
surface of B cells during the early stages of development within the bone marrow, IgD 
surface expression is also induced when immature B cells egress from the bone marrow 
in search of secondary lymphoid organs to finish maturation. The co-expression of IgM 
and IgD on the surface of transitional and mature B cells is controlled by the process of 
alternative RNA splicing and is tightly regulated by the B cell (25, 26). However, once 




by the B cell process of CSR through both T-cell independent and T-cell dependent 
pathways (33). After CSR occurs, B cells can further differentiate into plasmablasts that 
begin to secrete large amounts of their respective class switched immunoglobulin 
isotype.  These secreted antibodies then enter circulation to carry out their various 
effector functions. Secreted IgD is distinctive from the other antibody classes and 
therefore carries out distinctive effector functions. It is known that secreted IgD is found 
in high concentration within the human respiratory mucosa and one of its functions is 
binding to respiratory pathogens such as: Moraxella catarrhalis and Haemophilus 
influenzae, however the most well-known function of secreted IgD is to bind to galectin-
9 on basophils, thus amplifying humoral T helper 2 cell responses by activating basophil 
release of antimicrobial, opsonizing, proinflammatory and B-cell stimulating factors such 
as: cathelicidin, interleukin 1(IL-1), IL-4, and BAFF (33, 56).  The combination of these 
known functions suggests that secreted IgD may be able to educate basophils on the 
microbial composition of the respiratory tract, thus providing a critical component of 
immune system surveillance for both adults and children.  
Pathogenic microbes within the respiratory tract pose a major health risk to 
children who do not have a fully developed immune system and infectious disease 
continues to be a leading cause of death for children aged 0 to 5 years old (58). 
Vaccination is highly effective at preventing these deadly infections, however newborn 
children do not mount efficient immune responses to most vaccines and are left 
particularly vulnerable (59). This neonate vulnerability to infectious disease was the 
driving force behind the development of maternal vaccination which is a safe and 
effective strategy that utilizes the immunization of pregnant woman to boost maternal 




humoral immune system during pregnancy are essential to the success of maternal 
vaccination. Efficient vaccine responses rely on the generation of plasmablasts and the 
secretion protective antibodies in large quantities. It has also been previously shown 
that plasmablasts specifically expand during pregnancy (68). Utilizing the expansion of 
plasmablasts during pregnancy is what makes maternal vaccination such an effective 
strategy in combating neonatal infection.  Currently, plasmablast secretion of IgG is the 
cornerstone of maternal vaccination because it is the only antibody class that has been 
extensively shown to cross the placenta. However after taking previous speculation by 
Salonen and colleagues into consideration (57), we then hypothesized that secreted IgD 
was capable of crossing the placenta and transferring immunity to the fetus.    
 In this study we show that IgD is fully capable of placental transcytosis both in 
vitro. Additionally, we demonstrate that placental transcytosis of IgD is significantly 
altered by cytokine signals, hormone signals, and post-translational protein 
glycosylation. Furthermore, we report that IgD co-localizes with cellular trafficking 
proteins in microscopy images of human placenta. Finally, while there was a reagent-
related issue in our mouse model for placental transcytosis of vaccine-specific IgD, we 
were able to utilize both maternal and cord blood serum samples to demonstrate that 










MATERIALS AND METHODS 
  In vitro placental transcytosis assays. The human villous trophoblast-derived 
BeWo cell line has been well established as a particularly useful model for studying 
placental transcytosis (86, 87). We followed the previously described protocol for this 
established in vitro placenta transcytosis assay and coated 0.2μm Transwell inserts with 
80μL of 250μg/mL cell culture grade placental collagen purchased from Sigma. After 
coating the Trasnwell inserts with placental collagen, BeWo cells were then seeded 
onto the Transwell membrane at a subconfluent concentration. The BeWo cells were 
then allowed to grow in culture for 5-7 days until Transwell confluency was reached and 
the cells became an intact polarized monolayer. After an intact confluent monolayer was 
observed, then various purified human antibodies, depending on experimental 
conditions, would be added into the apical chamber of the Transwell insert at a 
concentration of 50μg/mL. After addition of the antibody into the apical chamber of the 
Transwell insert, a 50μL sample would then be collected from the basolateral chamber 
of the cell culture wells at the 0 minute (min), 10 min, 30 min, 1 hour (hr), 2hr, and 4 hr 
time intervals. The 50μL collected samples would later be analyzed by ELISA to show 
the amount of antibody transferred from the apical chamber to the basolateral chamber.  
The capture antibody and detection antibody for human IgD used in these ELISAs were 
both purchased from Bethyl Labratories. The goat anti human IgD capture antibody was 
diluted 100-fold before coating the ELISA plate and the goat anti human IgD-HRP 
conjugated antibody was diluted 50,000-fold for detection. The purified human 
antibodies that were utilized in the apical chamber of all the BeWo transcytosis assays 




Enzymatic deglycosylation of human IgD. Purified human IgD was 
enzymatically stripped of its post-translational N-linked and O-linked glycans by 
following the manufacturer specifications for the PNGase F, neuraminidase, and o-
glycosyidase enzymes purchased from New England Biolabs. After deglycosylation of 
the IgD heavy chain was confirmed by SYPRO Ruby stain of an SDS-PAGE gel, the 
deglycosylated human IgD was then utilized in a BeWo transcytosis assay as previously 
described.   
Tdap maternal vaccination mouse model. BALB/c mice were purchased from 
Jackson laboratory and IgD -/- mice were graciously provided to us by the Cerutti lab at 
Cornell university. Female mice were either unimmunized/not vaccinated (control/NV) or 
received 3 separate 100μL doses of intramuscularly administered Boostrix (aka Tdap) 
7, 14, and 21 days before pregnancy. A 4th 100μL dose of Tdap was then administered 
on either gestational day 4.5 or 14.5 to the previously immunized mothers. Immediately 
following delivery, maternal and pup blood samples were collected, and all mice were 
euthanized. Serum from the collected blood samples was then used in an ELISA to 
determine the presence of Tdap-specific IgD. The ELISA plate was coated with 10-fold 
diluted Tdap and all serum samples were diluted 10-fold for measurement. The 
detection antibody used in this ELISA was diluted 50,000-fold and is a goat anti mouse 
IgD-HRP conjugated antibody purchased from American Research Products. It is 
currently the only anti mouse IgD-HRP conjugated detection antibody on the market 






Tdap-specific IgD placental transcytosis in humans. Pregnant DMC hospital 
patients were informed of our research project and signed medical consent forms giving 
us permission to collect their blood, cord blood and placenta tissues. The medical 
consent forms were approved by the Wayne State University IRB. The first maternal 
blood sample was collected immediately prior to the pregnant mother receiving her 
Tdap vaccination to establish her baseline antibody levels. The second maternal blood 
sample was collected 2-4 weeks later at her next healthcare visit to show that Tdap-
specific IgD had been induced by vaccination. The third maternal blood sample as well 
as the cord blood sample was collected upon delivery of the baby to determine the 
Tdap-specific IgD levels at birth. Following full term delivery, the placenta was also 
collected and stored for immunofluorescent confocal images. The collected human 
blood samples were analyzed by ELISA to show their Tdap-specific IgD antibody titers. 
The ELISA plate was coated with 10-fold diluted Tdap, the human serum samples were 
diluted 10-fold and the goat anti human IgD-HRP antibody was diluted 50,000-fold for 














IgD undergoes placental transcytosis in vitro. By utilizing a well-established 
human villous trophoblast-derived cell line (BeWo) transcytosis assay (86, 87), we 
found that both human IgG and IgD undergo apical-to-basolateral transcytosis while IgM 
and IgA do not (Figure 1A). The lack of IgM and IgA placental transcytosis in vitro is 
consistent with their inability to cross the placenta in vivo. In order to confirm the 
integrity of the cellular monolayer, confocal images were taken of the cells following the 
BeWo transcytosis assay and their integrity was confirmed with the expression of the 
tight junction protein zonular occludin-1 (ZO-1) (Figure 1B). Additionally, in the confocal 
images IgD can be seen in what appears to be intracellular vesicles and perinuclear 
structures that bear a resemblance to cellular trafficking organelles. Furthermore, the 
cellular monolayer integrity was confirmed by the lack of detectable basolateral 
immunoglobulin within the first 10 minutes of the assay.  
Cytokine and hormone signals modulate placental transcytosis of IgD in 
vitro. It has been demonstrated that both placental infection and placental inflammation 
have the ability to compromise the transfer of antibodies and metabolites to the fetus 
(88-91). Our results show that TH1, TH17, and Treg cytokine signals significantly inhibit 
the placental transcytosis of IgD in vitro (Figure 2A, C, D) where as TH2 cytokine 
signals had no effect on IgD placental transcytosis (Figure 2B). Furthermore, our 
results show that adrenocorticotropic hormone (ACTH) and 17β-estradiol hormone 
signals significantly inhibit placental transcytosis of IgD in vitro while progesterone 





Post-translational glycosylation of IgD is required for efficient placental 
transcytosis in vitro. The glycosylation of IgD has been shown to be distinct from the 
glycosylation of other antibody subclasses and it has been speculated that the unique 
structural characteristics of IgD contribute to its unique biological properties (34-42). 
Treatment of IgD with neuraminidase and o-glycosidase to enzymatically remove all O-
linked glycans and treatment of IgD with PNGase F to enzymatically remove all N-linked 
glycans resulted in the expected reduction of IgD heavy chain molecular weight (Figure 
3A). After enzymatic removal of N-linked and O-linked glycans from IgD was confirmed, 
the carbohydrate-less IgD was then used in an in vitro BeWo transcytosis assay where 
it demonstrated that a lack of O-linked glycans and a lack of N-linked glycans both 
resulted in a significant reduction in IgD placental transcytosis (Figure 3B).  
IgD binding to BeWo cells is enhanced by galectin-9. The binding of IgD to 
galectin-9 on the surface of basophils has already been shown (56), however the 
binding of IgD to galectin-9 on the surface placental cells has not been demonstrated 
until now. We show using flow cytometry that IgD binding to BeWo cells was noticeably 
increased by an incubation with galectin-9 prior to cell exposure, but not with a galectin-
1 or galectin-3 incubation prior to cell exposure (Figure 4). These results suggest that 
galectin-9 may be directly involved in the transcytosis of IgD across BeWo cells.  
Cellular trafficking of IgD in human placenta. Progressing forward from our 
cell line-based transcytosis assays, we then used primary human placenta from full term 
deliveries to detect the presence of IgD. Indeed, confocal images show IgD colocalizing 
with the early endosome marker EEA-1, the trans-golgi network marker TGN-46, and 
the basolaterally targeting cellular trafficking protein CD44 (Figure 5A-C). These 




human placenta and further corroborate our earlier data from the BeWo transcytosis 
assays where we observed IgD in what appeared to be intracellular vesicles and 
perinuclear structures (Figure 1B).  
Reagent issue in Tdap maternal vaccination mouse model. We were able to 
show by ELISA that wild type (WT) BALB/c mothers will significantly generate Tdap-
specific IgD in response to immunization, and that this Tdap-specific IgD is easily 
detectable in the serum of pups whose mothers had received a Tdap vaccination on 
either gestational day 4.5 or gestational day 14.5 (Figure 6A). Furthermore, the 
vaccination series that the WT mothers received had no significant effect on the 
gestational length of the pregnancy or on the birth weight of the pups, suggesting that 
this maternal vaccination mouse model is safe and has no adverse effects to the fetus 
(Figure 6B). However, after applying the previously mentioned Tdap maternal 
vaccination series to IgD-/- female mice, an issue was observed in the data. We 
observed by ELISA that IgD-/- mothers who had received the Tdap vaccine supposedly 
display significant levels of “Tdap-specific IgD” in their serum and both the IgD+/- and 
IgD-/- pups of these vaccinated mothers also contained “Tdap-specific IgD” in their 
serum (Figure 6C). When comparing serum from entire litters of IgD+/- pups to serum 
from entire litters of IgD-/- pups, we noticed that IgD+/- pups from vaccinated IgD-/- 
mothers displayed slightly higher levels of  “Tdap-specific IgD” than the IgD-/- pups from 
vaccinated IgD-/- mothers, suggesting that the antigens from the Tdap vaccine may 
possibly be crossing the placenta and thus priming the fetal immune system to generate 
its own “Tdap-specific IgD”. After this observation, we designed a mating scheme that 
allowed for the generation of IgD+/- pups and IgD-/- pups within the same litter and 




mother. We found that “Tdap-specific IgD” was detectable in both IgD+/- pups and IgD-/- 
pups but there was no significant difference in “Tdap-specific IgD” serum levels of IgD+/- 
pups and IgD-/- pups from the same litter. These results suggest that fetal immune 
priming is not taking place within this Tdap maternal vaccination mouse model (Figure 
6D). After confirming that IgD is in fact removed from the genome of the IgD-/- mice used 
throughout Figure 6 and the presence of Tdap-specific IgD within the IgD-/- mice is 
biologically impossible, we conclude that the detection antibody used in the ELISAs is 
nonspecifically binding to Tdap-specific IgG and this nonspecific binding is the sole 
reason for our observed data issue.  
Placental transcytosis of maternally induced Tdap-specific IgD in humans. 
We wanted to determine whether or not placental transcytosis of IgD could also be 
readily observed within pregnant humans. By obtaining blood samples from pregnant 
women prior to Tdap vaccination and blood samples 2-4 weeks following their Tdap 
maternal vaccination, we were able to demonstrate by ELISA that there was a marked 
increase in total antibody titer of Tdap-specific IgD following vaccination, thus showing 
that Tdap-specific IgD was readily induced in humans by maternal vaccination (Figure 
7A).  Additionally, maternal blood samples and cord blood samples were obtained 
immediately following birth for ELISA. We observed that there is a substantially higher 
Tdap-specific IgD antibody titer in cord blood samples than there is in maternal blood 
samples at delivery, thus suggesting that maternally induced Tdap-specific IgD does in 








Our findings indicate that the current widespread ideology of IgG being the only 
maternal antibody transferred to the fetus during pregnancy is not entirely correct, and 
that IgD is fully capable of crossing the placenta. The BeWo transcytosis assay has 
proven to be an excellent in vitro model to study placental transfer of IgD and the 
cytokine/hormone signal modulation of IgD placental transcytosis in BeWo cells has 
provided us with some very insightful information. Placental infection and placental 
inflammation can compromise the transfer of antibodies to the fetus (88-91), so it is 
expected that the proinflammatory TH1 and TH17 cytokines used in Figures 2A and 2D 
would result in a significant reduction in BeWo transcytosis of IgD. Additionally, it is not 
surprising that the TH2 cytokines in Figure 2B have no effect on BeWo transcytosis of 
IgD because these cytokines are required for B cell CSR, which is a major pathway for 
the induction of secreted IgD. However, the idea of the Treg cytokine TGF-β significantly 
reducing the BeWo transcytosis of IgD initially seemed slightly perplexing, but upon 
searching the literature further this finding corroborates the data we observed in our 
confocal images of human placental tissue in Figure 5C where IgD co-localizes with 
CD44.  It has been demonstrated that TGF-β signaling directly regulates the alternative 
splicing of CD44, thus controlling which CD44 isoform is actually expressed by the cell 
(92), and it has also been shown that CD44 is involved with IgD binding to the surface 
of basophils (56). Therefore, treating the BeWo cells with TGF-β may have directly 
changed the normally expressed CD44 isoform to another isoform with different protein 
binding properties in comparison to the normal placental CD44 isoform, ultimately 
resulting in a significant reduction of BeWo IgD transcytosis from TGF-β treatment. It is 




determine why the progesterone treatment in Figure 2E resulted in such a significant 
increase in BeWo transcytosis of IgD. 
Furthermore, the use of deglycosylated IgD in a BeWo transcytosis assay has 
also provided us with some valuable information towards the future direction of 
researching IgD placental transcytosis. It has previously been shown that the effector 
functions of IgG, mediated through the FcγR, are severely compromised when IgG is 
deglycosylated due to a lack of FcγR binding (93). Our results show that a lack of N-
linked glycans resulted in the biggest reduction of BeWo IgD transcytosis. These 
observations suggest that the two distinctive N-linked glycans in the Cδ3 domain of IgD 
may be directly involved in the binding of an unidentified placental IgD receptor. This 
unidentified placental IgD receptor may possibly be galectin-9 but this has yet to be 
confirmed.   
 As previously stated, there was an issue observed in our Tdap maternal 
vaccination mouse model results, however we believe this issue is only reagent-related 
and the results do not prove our original hypothesis wrong. During the vaccination 
series of the IgD-/- mothers in Figures 6C and 6D it is impossible for them to actually 
generate a vaccine-specific IgD response because IgD has been removed from their 
genome, yet “vaccine-specific IgD” is readily observed in serum of IgD-/- mothers after 
performing a vaccine specific ELISA. While these vaccinated IgD-/- mothers are 
physically incapable of producing vaccine specific IgD they are still fully capable of 
producing a robust vaccine specific IgG response because IgG is still present in their 
genome. This vaccine specific IgG generated within the vaccinated IgD-/- mothers is still 
readily transferred across the placenta to her IgD-/- pups. This means that the only 




mothers and pups is that the antibody we used for detection of mouse IgD in the ELISA, 
not only binds to mouse IgD but also nonspecifically binds to mouse IgG. If there was 
another company that sold a different anti-mouse IgD-HRP conjugated antibody this 
technical discrepancy could be easily mediated, unfortunately this is not the case and 
the antibody we used is currently the only one of its kind. This Tdap maternal 
vaccination mouse model will not be able to provide conclusive results of IgD placental 
transcytosis until an anti-mouse IgD-HRP conjugated antibody with much less 
nonspecific binding is developed.  
This study shows that IgD is fully capable of placental transcytosis both in vitro. 
We demonstrated that placental transcytosis of IgD is significantly altered by cytokine 
signals, hormone signals, and post-translational protein glycosylation. Furthermore, we 
report that IgD co-localizes with cellular trafficking proteins in microscopy images of 
primary human placenta. Although our Tdap maternal vaccination mouse model 
remains inconclusive in determining the placental transcytosis of vaccine-specific IgD, 
we were able to utilize both maternal and cord blood serum samples to demonstrate 

























FIGURE 1. Placental transfer of IgD in vitro. (A) Kinetics of apical-to-basolateral 
transcytosis of human IgM, IgG, IgA, and IgD across intact confluent layer of BeWo 
cells, as determined by ELISA. 50ug/mL of each Ig class was added to the apical side 
at the beginning of the assay (B) Confocal image of IgD transcytosing BeWo cell layer 
expressing the tight junction protein zonular occludin-1 (ZO-1) captured following 
transcytosis assay. Arrowheads point to IgD staining visible in intracellular vesicles. 




















































FIGURE 2. Placental transfer of IgD in vitro is modulated by cytokine and hormone 
signals. Confluent BeWo cell layers were either untreated (Nil) or treated for 24 hr with 
50ng/mL of IFN-γ or TNF-α (A), IL-4 or IL-33 (B), IL-10 or TGF-β (C), IL-17A or IL-22 (D) 
or 100nM of progesterone or 17β-estradiol or 1μM of ACTH (E), prior to the IgD 































































































































FIGURE 3. Placental transfer of deglycosylated IgD in vitro. (A) SYPRO Ruby stain of 
an SDS-PAGE gel of human IgD treated with deglycosylation enzymes and/or buffer, 
showing a reduction of IgD H chain size after N- and/or O-deglycosylation. PNGase F 
(36kDa) cleaves N-linked glycans, whereas neuraminidase (43 kda) and O-glycosidase 
(147kDa, Not shown in image) together remove O-linked glycans (B) Kinetics of 
transcytosis of IgD prepared in (a) across BeWo cells. *:p<0.05 as compared to IgD + 
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FIGURE 4. Galectin-9 enhances IgD binding to BeWo cells. (A) IgD staining on BeWo 
cell surface after incubation with 50μg/mL IgD with or without 2.5 μg/mL Galectin-1, 
Galectin-3, or Galectin-9 @ 4C for 10 min. Shaded histogram indicates IgD staining 




































FIGURE 5. Confocal images of IgD Cellular Trafficking in Human Placenta. (A) Confocal 
immunofluorescence analysis of IgD (green) and EEA-1 (red) in term placenta villi. DNA 
stained with DAPI. Bars: 100 μm (left panel) or 30 μm (other panels). (B) Confocal 
immunofluorescence analysis of IgD (red) and TGN-46 (green) in term placenta villi. 
DNA stained with DAPI. Bars: 50 μm. (C) Confocal immunofluorescence analysis of IgD 
(green) and CD44 (red) in term placenta villi. DNA stained with DAPI. Bars: 50 μm. 
(A,B,C) V: villi, IVS: intervillious space. All images are representative of placental 
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FIGURE 6. Reagent issue in the detection of maternally induced Tdap-specific IgD 
undergoing placental transfer in mice. (A) ELISA of Tdap-specific IgD in maternal and 
newborn pups’ blood at delivery. The mothers were either unimmunized (control) or 
received 3 doses of intramuscular Tdap 7, 14, and 21 days before pregnancy and a 4th 
dose on gestational day (gd) 4.5 or 14.5. (B) Comparison of gestational length and pup 
birth weight of control and immunized mothers from (Figure 6A). (C) ELISA of Tdap-
specific IgD in maternal (IgD-/-) and newborn pups’ (IgD+/- and IgD-/-) blood at delivery. 
The IgD-/- females (F) were either not vaccinated (NV) or received 3 doses of 
intramuscular Tdap 7,14, and 21 days before pregnancy and a 4th dose on gestational 
day 4.5 (V) after being mated with either WT or IgD-/- males (M). (D) ELISA of Tdap-
specific IgD in newborn pups’ (IgD+/- and IgD-/-) blood at delivery. The IgD-/- females (F) 
received 3 doses of intramuscular Tdap 7,14, and 21 days before pregnancy and a 4th 
dose on gestational day 4.5 after being mated with IgD+/- males (M). All serum samples 
were diluted 10-fold for measurement. *:p<0.05; **:p<0.01; ***:p<0.001 by 1-tailed 









FIGURE 7. Maternally induced Tdap-specific IgD undergoes placental transfer in 
humans. (A) ELISA measurement of Tdap-specific IgD titers in maternal peripheral 
blood before vaccination (black lines, Pre Vac), 2-4 weeks after vaccination (red lines, 
Post Vac), at delivery (green lines) and in cord blood (blue lines) of 3 representative 
responders and 1 subject that already had a detectable antibody titer before 
vaccination.*:p<0.05; **:p<0.01 by 1-way repeated measures ANOVA with a Dunnett’s 
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 Immunoglobulin D is a mysterious protein that has largely been overlooked since 
its discovery. It is uniquely distinct from all the other antibody classes in: expression, 
induction, structure and function. Within the last few years IgD has made its way back 
into the spotlight and novel functions of the protein have been discovered. These recent 
discoveries have provided the necessary information for us to uncover an additional and 
important function of IgD during pregnancy. It is a long-held belief among scientists that 
during pregnancy the only antibody class that can cross the placenta is IgG, however 
our data shows that this common place ideology is not correct. We find that IgD is fully 
capable of crossing the placenta and that vaccine-specific IgD induced by maternal 
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